Shanghai Ark Biopharmaceutical Co., Ltd (ArkBio), a Chinese biopharmaceutical company, has entered into a partnership with SDODT, a domestic innovator in digital therapeutics technology. The collaboration aims to enhance the marketing and commercialization efforts for products targeting Attention Deficit Hyperactivity Disorder (ADHD) treatment.
ADHD is a prevalent chronic neurodevelopmental disorder that typically emerges in childhood and may extend into adulthood. It is characterized by significant inattention and/or hyperactivity that exceeds developmental norms. Individuals with ADHD often face behavioral challenges, learning disabilities, and other related issues. Timely detection and intervention are crucial for managing ADHD effectively.
Ark Biopharma possesses Azstarys, an ADHD therapy that combines serdexmethylphenidate and dexmethylphenidate and is FDA approved. The drug contains SDX, a prodrug of dexmethylphenidate, which offers rapid onset of action within 30 minutes and provides continuous control of ADHD symptoms for up to 13 hours. The company secured exclusive development and marketing rights for Azstarys through an agreement with Commave in December 2021, followed by conducting a regulatory bridging study in China in 2023.- Flcube.com
